BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

論壇議程總覽

2023 亞洲生技論壇

​​

BIO Asia–Taiwan 2023
Conference Agenda 

Date July 26-28, 2023

Venue July 26 TaiNEX2 + Online event platform
July 27-28 TaiNEX1 + Online event platform

Day 1 - Wednesday, July 26
Day 2 - Thursday, July 27
Day 3 - Friday, July 28

09:00 – 10:30

Session 1 (Plenary) – Global Biotech Development
701EF, 7F, TaiNEX2

Novel medical technologies and drug platforms such as mRNA and lipid nanoparticles are revolutionizing healthcare, with applications in such critical areas as cancer treatment, rare diseases, and novel vaccines. We are honored to have join us today three recipients of the international Tang Prize in Biopharmaceutical Science, awarded for their role in developing mRNA vaccines, to examine what the future holds for these exciting new technologies. Join us for a thought-provoking and informative session on the cutting edge of drug development technologies.

09:00 – 10:30 Session 1 (Plenary) – Global Biotech Development
09:00 – 09:05 Welcome

Johnsee Lee, Chairman of BIO Asia–Taiwan 2023

09:05 – 09:15 Opening Address
09:15 – 09:20 VIP Remarks

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

09:20 – 09:30 Opening Ceremony for Conference
09:30 – 09:45 Nucleoside-modified mRNA-LNP Therapeutics

Drew Weissman, Professor, University of Pennsylvania, 2022 Tang Prize Laureate

09:45 – 10:00 Design of Lipid Nanoparticles That Enable Gene Therapies

Pieter Cullis, Professor, University of British Columbia, 2022 Tang Prize Laureate

10:00 – 10:15 Developing mRNA for Therapy

Katalin Karikó, Professor of University of Pennsylvania and senior vice president of BioNTech RNA Pharmaceuticals, 2022 Tang Prize Laureate

10:15 – 10:25 Break

10:25 – 12:10

Session 2 (Plenary) – Global Biotech Development
701EF, 7F, TaiNEX2

The Asia Pacific region has become a hotbed of biotech investment. This session will explore the latest trends and opportunities in this space, with a special focus on Taiwan. Hear from industry leaders on the factors driving investment in the region, the challenges and opportunities for startups, and the outlook for future growth. We’ll also examine Asia’s role as a major clinical trials hub, and the latest innovations and best practices for conducting efficient and effective trials. Join our expert speakers as they examine the fast-evolving regulatory landscape, the impact of digital technologies, and the potential for new approaches to improve patient outcomes.

10:25 – 12:10 Session 2 (Plenary) – Global Biotech Development
10:25 – 10:40 Growth Opportunities in Precision Health: Moving from Sickcare to Healthcare

Reenita Das, partner and senior vice president in healthcare and life sciences global, Frost & Sullivan

10:40 – 10:55 “Brave New World”-Pharma in post-COVID Era

Graham Lewis, Vice President, Global Pharma Strategy, IQVIA

10:55 – 11:10 2023 Health Trends: Pacing Up in Clinical Development

Syneos Health

11:10 – 11:25 Accelerate Digital Tech Transfer from Research to Development to Manufacturing Adhering Quality

Basha Kodidela, Senior Manager – Technical Sales APAC, BIOVIA

11:25 – 11:40 Post-covid Trends in Biotech and Pharmaceutical CDMO and Supply Chain (TBD)

Jens Neumann, Partner, Pharmaceutical and Life Sciences Operations Leader in Europe, PwC Strategy& (Germany) GmbH

11:40 – 12:10 Panel Discussion and Comments

Moderator: Johnsee Lee, Chairman of BIO Asia–Taiwan 2023
Panelists:

12:20 – 13:50

Session 3 – From great to excellent: Develop Taiwan medical care to become a global best practice
701EF, 7F, TaiNEX2

The biotech industry is increasingly global in scope, with international collaboration considered an essential element for success. This session will delve into the strategies and best practices for collaboration between multinational companies and local partners, and examine the challenges and opportunities that arise from cross-border partnerships. Gain an understanding of how multinational companies can support Taiwan's precision healthcare development goals, including the sharing of resources, expertise, and infrastructure. We’ll also explore the clinical trial ecosystem, focusing on the latest trends and innovations in trial design and implementation, and highlighting the importance of collaboration between academia, industry, and regulatory bodies.

14:00 – 15:30

Session 4 – How to Bring New Drugs to Global Markets?
701EF, 7F, TaiNEX2

This session will focus on the key factors to successfully launching new products onto world markets; technology, utilizing AI, for example; reimbursement, understanding both policy and current practices; patient diversity; and economics, including tapping investment and capital markets. Speakers will share experience and insights on navigating regulatory environments, managing clinical trials, and addressing the needs of patients and stakeholders. The session will also highlight the latest innovations in drug development, such as precision medicine and digital health technologies, and the potential for these approaches to improve patient outcomes and streamline the drug development process. Attendees can expect to gain valuable insights into what it takes for successful global drug development.

14:00 – 15:30 Session 4 – How to Bring New Drugs to Global Markets?
14:00 – 14:05 Opening Remarks
14:05 – 15:30 Panel Discussion

Moderator:
John Tsai, Former President Global Drug Development & CMO of Novartis; Blueprint Medicines Board member
Panelist:

  • Luk Vandenberghe, Associate Professor at Harvard Medical School & an Associate Member of the Broad Institute of Harvard & MIT. Founder, AKOUOS
  • Feng Ren, Co-CEO & CSO, Insilico Medicine
  • Gur Roshwalb, Partner, aMoon
  • Melika Davis, SVP & Global Head, Clinical Operations, BeiGene

 

15:40 – 17:10

Session 5 – Invest for 2024 and Beyond
701EF, 7F, TaiNEX2

Despite the challenging capital market environment of 2022, the Asian biotech and healthcare sector demonstrated resilience and even growth, significantly outperforming the main indices in markets across the greater Asian region. However, in a cautious investment environment, biotech companies must look to alternative funding sources to support research-intensive programs. This session has assembled top Asian investment bankers and financial professionals from leading institutions to discuss capital funding strategies and future opportunities and challenges for the biotech industry across Asia. Speakers include senior representatives from Goldman Sachs, Citigroup, and NASDAQ. Join us for an enlightening discussion on biotech investing for 2024 and beyond.

15:40 – 17:10 Session 5 – Invest for 2024 and Beyond
15:40 – 15:45 Opening Remarks

Joseph Chou, Chairman and CEO, PwC Taiwan

15:45 – 17:10 Panel Discussion

Moderator:
Peter Kurz, Chief Strategy Officer, QIC International
Panelist:

  • Sam Thong, Managing Director, Goldman Sachs
  • Makiko Iwai, Head of Healthcare IB, Citi Group
  • David Chen, Vice Director, Business Development Greater China, Nasdaq
  • Michael Brinkman, Managing Director, Joint US Head of Biopharmaceuticals Investment Banking, Jefferies, LLC

 

09:00 – 10:30

Session 6 – BIO Asia–Taiwan 2023 Opening & Award Ceremony (By Invitation Only)
4F, TaiNEX1

09:00 – 09:30 Admission
09:30 – 09:35 Introducing Honorable Guests
09:35 – 09:37 Welcome Remarks

Johnsee Lee, Chairman of BIO Asia–Taiwan 2023

09:37 – 09:43 Opening Speech
09:43 – 09:46 VIP Remarks

Rachel King, CEO, Biotechnology Innovation Organization

09:46 – 10:05 2023 Taiwan BIO Awards Ceremony
10:05 – 10:15 Ribbon-cutting Ceremony
10:15 Adjourn

10:40 – 12:00

Session 7 – Sharing Biotech Successes-Taiwan BIO Awardee Showcase
401, 4F, TaiNEX1

10:40 – 12:00 Sharing Biotech Successes-Taiwan BIO Awardee Showcase
10:40 – 10:45 Opening Remarks

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
President, Development Center for Biotechnology

10:45 – 12:00 Sharing the Experience of Biotech Success
2023 Taiwan BIO Awards Winners:

- Outstanding Company of the Year
- Emerging Company of the Year
- Innovation of the Year

12:20 – 13:50

Session 8 – Crossing Borders, Establishing a Global Biotech Ecosystem
401, 4F, TaiNEX1

Innovation is at the heart of the biomedical industry. In this session we’ll explore the latest innovation strategies that are driving success in the sector, both in Asia and the rest of the world. Speakers will discuss the importance of fostering a culture of innovation, and highlight the latest tools and methodologies for generating new ideas and driving creativity. Explore the role of collaboration and partnerships in driving innovation, and provide insights into successful innovation strategies. Attendees can expect to gain a deeper understanding of the innovation landscape in biotech, and learn about the strategies and best practices that are fueling growth and success in the industry.

12:20 – 13:50 Session 8 – Crossing Borders, Establishing a Global Biotech Ecosystem
12:20 – 12:30 Welcome Remarks
  • Representative from MOEA, Taiwan (Inviting)
  • Eric Y. Chuang, General Director, Biomedical Technology and Device Research Laboratories, ITRI
Opening Remarks
  • Jeffrey Dutton, Commercial Officer, American Institute in Taiwan (AIT)
Group Photo
12:30 – 12:45

Eric Y. Chuang, General Director, Biomedical Technology and Device Research Laboratories, ITRI

12:45 – 13:00

Sipra Bond, Vice President EM&E Supply Chain, Johnson & Johnson

13:00 – 13:15

Arthur Stephen, Vice President R&D ENDOMECHANICAL, Johnson & Johnson

13:15 – 13:50 Panel Discussion: Crossing Borders, Establishing a Global Biotech Ecosystem

14:00 – 15:30

Session 9 – New Asian Age
401, 4F, TaiNEX1

The COVID-19 pandemic changed the biomedical industry forever, accelerating the utilization of forward-looking technologies, shortening time-consuming research and development processes, and reducing time-to-market for many products. In this session we’ll examine investment trends in this newly re-imagined industry, as well as new business models. Understand how companies can expand through both vertical integration and horizontal expansion, and re-build resources into a strategic foundation that can respond quickly and grow steadily. Whether you are looking to expand your business into Asia or collaborate with Asian partners, this session will equip you with the knowledge and tools you need to succeed in this dynamic and rapidly growing market.

14:00 – 15:30 Session 9 – New Asian Age
14:00 – 14:10 Navigating the APAC Biotech Landscape Ahead

Jerome Shen, General Partner, Bio Fund, Taiwania Capital Management Corp.

14:10 – 14:30 New Modalities in Biotech.

Roger J. Pomerantz, Chairman of the Board, Viracta Therapeutics

14:30 – 14:50 Topic TBD

Leo Lee, President, Novartis Japan

14:50 – 15:25 Panel Discussion: Navigating Cross-border Collaborations in Drug Development:
Lessons Learned and Future Opportunities

Moderator: Victoria Wang, Principal, Bio Fund, Taiwania Capital Management Corp.
Panelists:

  • Frederick Shane, Managing Partner, Axil Capital
  • Leo Lee, President, Novartis Japan
  • Rick Tsai, Partner, Axil Capital
  • Wendy Huang, Chair & CEO, AnnJi Pharmaceutical
15:25 – 15:30 Closing Remarks

Michael Huang, Managing Partner, Bio Fund, Taiwania Capital Management Corp.

15:40 – 17:10

Session 10 – Clinical Impacts of Precision Health
401, 4F, TaiNEX1

This session will explore the latest developments and innovations at the intersection of precision health and clinical medicine. Examine the latest diagnostic tools and technologies driving the uptake of precision health, including next-generation sequencing for identifying treatment targets. Participants can expect to gain a deeper understanding of the ways in which precision health is transforming clinical practice and healthcare overall, and learn about the latest developments in moving from trial to treatment. This is a must-attend session for anyone looking to stay at the forefront of the rapidly evolving precision health landscape.

15:40–17:10 Session 10 – Clinical Impacts of Precision Health
15:40-15:45 Opening Remarks

Huey-Kang Sytwu, President, National Health Research Institutes

Moderator:

Shih-Feng Tsai, Distinguished Investigator, National Health Research Institutes

15:45-16:00 Paving the Way of Precision Medicine with Next Generation Diagnostics (TBD)

Helen Chen, Global Sector Co-Head, Healthcare and Life Sciences, L.E.K Consulting

16:00-16:15 Pharmacoeconomic Analysis of Precision Medicine (TBD)

Suzanne McGurn, President and Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health (CADTH) (Inviting)

16:15-16:30 Evident-based Decision to Enhance the Value of Precision Health (TBD)

Speaker from NHS or NICE (Inviting)

16:30-16:45 HTA of Precision Medicine Diagnostics in Korea

Jeonghoon Ahn, Professor, Department of Health Convergence, Ewha Womans University

16:45-17:10 Panel Discussion

Moderator: Chris Tsai, Chairman, Precision Medicine Industry Association of Taiwan
Panelists:

  • Chung-liang Shih, Director General, The National Health Insurance Administration of the Ministry of Health and Welfare
  • Wendy Kay Chung, Professor, Clinical Genetics and Genomics, Irving medical center of Columbia University
  • Suzanne McGurn, President and Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health (CADTH)(Inviting)
  • Jeonghoon Ahn, Professor, Department of Health Convergence, Ewha Womans University
  • Chih-Hsin Yang, Superintendent, National Taiwan University Cancer Center Hospital (NTUCC)
  • Helen Chen, Global Sector Co-Head, Healthcare and Life Sciences, L.E.K Consulting
  • NHS or NICE Speaker

09:00 – 10:30

Session 11 – Cell and Gene Therapies with Novel Enabling Platform
401, 4F, TaiNEX1

This session will showcase the latest novel biotech platforms from around the world. Speakers from both academia and industry will explore the cutting-edge technologies and platforms that are changing the game, from next-generation gene editing tools to revolutionary new drug delivery systems. Attendees can expect to gain a deeper understanding of the latest developments in biotech research and innovation, and learn about the most promising new platforms. Stay ahead of the curve and explore the latest advances that are driving biotech research and innovation to new heights. Don’t miss out on this must-attend session!

09:00 – 10:30 Session 11 – Cell and Gene Therapies with Novel Enabling Platform
09:00 – 09:05 Opening Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

09:05 – 09:15 Frontier in Gene and Cell Therapies

John Tsai, Former President Global Drug Development & CMO of Novartis; Blueprint Medicines Board member

09:15 – 09:30 Gene Therapy at a Crossroads

Luk Vandenberghe, Associate Professor at Harvard Medical School & an Associate

09:30 – 09:45 Managing a Robust Logistic System for Cell and Gene Therapies

Wen-Chyi Shyu, CEO, BRIM Biotechnology; Vice President, Head of Global Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical International Company

09:45 – 10:00 Cancer Proteomics and Biomarker Landscape of Advanced Therapies

Yu-Ju Chen, Distinguished Research Fellow, Institute of Chemistry, Academia Sinica

10:00 – 10:15 The Perfect Storm of Challenges in Cell and Gene Therapy Clinical Development and Commercialization

Wei Wang, Cooperate and Business Development Director, Cell and Gene Therapy, Syneos Health

10:15 – 10:30 Panel Discussion

Moderator: Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
Panelists:

  • John Tsai, Former President, Global Product Development & Chief Medical Officer, Novartis
  • Luk Vandenberghe, Associate Professor at Harvard Medical School & an Associate
  • Wen-Chyi Shyu, CEO, BRIM Biotechnology; Vice President, Head of Global Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical International Company
  • Yu-Ju Chen, Distinguished Research Fellow, Institute of Chemistry, Academia Sinica
  • Wei Wang, Corporate & Business Development, Strategic Planning, and Commercialization Executive, Syneos Health

10:40 – 12:10

Session 12 – New Modalities to Cure
401, 4F, TaiNEX1

Explore the latest and most promising new therapeutic modalities that are transforming healthcare today. Discover exciting new therapies as well as the latest drug development innovations; including gene and cell therapies, RNA-based therapies, and next-generation biologics. Learn from our panel of leading industry experts from Asia and around the world as they examine the latest trends, developments and future possibilities in therapeutics.

10:40 – 12:10 Session 12 – New Modalities to Cure
10:40 – 10:45 Opening Remarks

Chung-Hsiun Wu, CEO, Development Center for Biotechnology

10:45 – 11:00 Accelerating Product Development and Commercial Success- Developing Manufacturing and Quality Control Strategy for siRNA Therapeutics

Lubomir Nechev, Senior Vice President CMC Development, Alnylam Pharmaceuticals

11:00 – 11:15 AAV Production Platform Development

Yvette Tang, Vice President of Drug Substance Technology, BioMarin Pharmaceutical

11:15 – 11:30 High Throughput Prediction of The Best Multi-Functional Molecules to Develop in The Clinic Through Preclinical Data Analysis

Ignacio Asial, Founder and CEO, DotBio

11:30 – 11:45 Clinical Trials of Nucleic Acid-based Pharmaceutics

Speaker from Syneos Health

11:45 – 12:10 Panel Discussion

Moderator: Chung-Hsiun Wu, CEO, Development Center for Biotechnology
Panelists:

  • Lubomir Nechev, Senior Vice President CMC Development, Alnylam Pharmaceuticals
  • Yvette Tang, Vice President of Drug Substance Technology, BioMarin Pharmaceutical
  • Ignacio Asial, PhD, Founder and CEO, DotBio
  • Speaker from Syneos Health

12:20 – 13:50

Session 13 – Empowering Patient-centric Digital Health
401, 4F, TaiNEX1

Digital health is a rapidly growing field with the potential to transform the way we approach healthcare. In this session, speakers will discuss the latest developments in digital health infrastructure development with a particular focus on Asia, and how these advancements are paving the way for a future of personalized, data-driven healthcare across the region. Understand the disruptive potential of the digital health revolution, and gain insights into the latest trends and emerging technologies that are shaping the industry. Whether you're a medical professional, investor, or simply interested in the future of healthcare in Asia and beyond, this session is for you.

12:20 – 13:50 Session 13 – Empowering Patient-centric Digital Health
12:20 - 12:25 Opening Remarks

Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association

12:25 - 12:40 Care Beyond Drug: Empowering Patient-centric Care with Digital Health Ecosystem

Jared Josleyn, Global Head of Digital Healthcare, Sanofi

12:40 - 12:55 Digital Health Innovation and Development from the Perspectives of the National Health Insurance

Chung-liang Shih, Director General, The National Health Insurance Administration of the Ministry of Health and Welfare

12:55 - 13:10 Digital Healthcare in APAC – A Sandbox For Patient-Centric And Commercial Innovations

David Xie, Partner, Deloitte Consulting

13:10 - 13:25 Reimbursement as Enabler to Innovation: Mindset and Framework to Overcome Challenges of the Healthcare Ecosystem

Josh Makower, Director, Stanford Byers Center for Bio Design

13:25 - 13:50 Panel Discussion

Moderator:
Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association
Panelist:

  • Chung-Liang Shih, Director General, National Health Insurance Administration of Taiwan
  • Jared Josleyn, Global Head of Digital Healthcare, Sanofi
  • Josh Makower, Director, Stanford Byers Center for Bio Design

14:00 – 15:30

Session 14 – Robust Manufacture for Cell Therapies and Biologic Drugs
401, 4F, TaiNEX1

With Asia a fast-growing global CDMO hub, we’ll deep dive into the latest trends, opportunities, and challenges facing the biomedical supply chain and contract manufacturing industries. Expert speakers will share their knowledge and experience in navigating complex regulatory landscapes, improving manufacturing processes, and enhancing supply chain resilience and agility. Whether you're a biotech industry professional, a healthcare provider, or an investor, this session offers a unique opportunity to stay up-to-date on the latest developments and best practices in supply chain and bio-manufacturing.

14:00–15:30 Session 14 – Robust Manufacture for Cell Therapies and Biologic Drugs
14:00-14:05 Opening Remarks

Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals & Bora Biologics
Lee-Cheng Liu, Dr. Sci. Eng., Founder, Chairman and President of EirGenix

14:05-14:45 Development and Manufacturing of Highly Engineered MAbs:

Moderator:
Robert Gustines, SVP Commercial Operations, Bora Biologics (TBD)
Panelist:

  • Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals & Bora Biologics
  • Andreas Nechansky, Managing Director, ABF Pharmaceutical Services
  • Ignacio Asial, Founder and CEO, DotBio
  • Rishi Bedi, CEO, Y-Trap, Ine. (inviting)
14:45-14:50 Break
14:50-15:30 Cell and Gene Therapy:

Moderator:
Lee-Cheng Liu, Dr. Sci. Eng., Founder, Chairman and President of EirGenix
Panelist:

  • Man-shiow Jiang, Executive Director, Viral Vector of Process Technology Development, WuXiApptec
  • Yuexia Li, Consultant, WE Conduit Consulting
  • Jae‑Hung Shieh, Memorial Sloan Kettering Cancer Center

15:40 – 17:10

Session 15 – Biodesign for the Future of MedTech
401, 4F, TaiNEX1

Don't miss this exciting session on the future of medtech! Our expert speakers will explore the latest health-tech innovations, and discuss strategies for connecting with innovators from across the APAC community. Gain valuable insights into emerging medical technology trends and opportunities, from the latest breakthroughs in devices to cutting-edge digital health solutions. With a focus on collaboration and cross-border partnerships, this session offers a unique opportunity to connect with industry leaders and explore new pathways to success in this dynamic and rapidly evolving industry. Get ready to be inspired, empowered, and energized as you explore the limitless potential of the medtech revolution!

15:40–17:10 Session 15 – Biodesign for the Future of MedTech
15:40–15:45 Opening Remarks

Taipei Medical University

15:45–16:00 Stanford Biodesign: The Origin and Future of Need-Driven Health Technology Innovation

Josh Makower, Director, Stanford Byers Center for Biodesign

16:00–16:15 APAC region: a Powerful Community of Innovators for the Health of the World

Anurag Mairal, Director, Global Outreach Programs at Stanford Byers Center for Biodesign

16:45–17:10 Panel Discussion

Moderator:

  • Jiunn-Horng Kang, Dean, College of Biomedical Engineering, Taipei Medical University
Panelist:
  • Meng-Huang Wu, CEO, Biodesign Center, Taipei Medical University
  • Lyn Denend, Director, Academic Programme, Stanford Byers Center for Biodesign
  • Matthew Oldakowski, Director, Biodesign Australia
  • Fumi Ikeno, Advisory Director, Japan Biodesign
  • Phin-Peng Lee, Deputy Program Director, Singapore Biodesign
  • Yona Vaisbuch, Program Director, Biodesign Israel
  • Nitin Sisodia, Fellowship Director, School of International Biodesign, AIIMS, New Delhi